Wisconsin will receive $4.27 million of the $181 million Risperdal marketing settlement that is being split among 37 states.
Risperdal is an anti-psychotic drug that has FDA approval to treat schizophrenia and bipolar disorder. Its manufacturer was sued for allegedly marketing the drug to treat dementia, a condition for which it is not approved.
The suit accuses the drug’s manufacturer, Janssen Pharmaceutical Inc., a subsidiary of Johnson & Johnson, of ghostwriting medical journal articles in order to promote it as a viable treatment for dementia. Company spokespeople say their settlement payment is not an admission of guilt, but a decision made to prevent a costly legal battle.
Product manufacturers have an obligation to the public to market their goods truthfully. If you have been hurt as a direct result of dishonest marketing, you can hold the product’s manufacturer accountable for your injuries. Contact the product liability attorneys of Habush Habush & Rottier S.C. ® at 800-242-2874 to learn more.